生体内におけるMaillard反応中間代謝産物3-deoxyglucosone(3-DG)の特異的定量

この論文をさがす

抄録

Maillard reaction, nonenzymatic glycation, has been suggested to play an important role in the pathogenesis of diabetic complications. 3-deoxyglucosone (3-DG) is known as a reactive crosslinker in advanced Maillard reaction in vitro, and a precursor of advanced glycosylation end products (AGEs) such as pyrraline and pentosidine, which have been previously detected in vivo. 3-DG was converted to a stable compound, 2-(2,3,4-trihydroxy butyl)-benzo [g] quinoxaline, by reacting with 2, 3-diaminonaphthalene. Since the derivative had a characteristic UV spectrum, it was determined at 268 nm by HPLC. Plasma 3-DG levels were significantly higher in streptozotocine induced diabetic rats compared with controls (918±134 nM vs. 379±69 nM, p<0.001), and were suppressed with the administration of aminoguanidine. Plasma pyrraline levels in diabetic rats also increased in parallel with elevated 3 -DG levels. These findings indicate that 3-DG is present in vivo even under normal conditions and that its level increases in diabetic condition. Determination of 3-DG in vivo may be a good tool to predict development and progression of diabetic complications, leading to the prevention of them. Furthermore, this assay will be useful to approach the treatment of diabetic complications by assessing the efficiency of inhibitors to Maillard reaction.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ